Iterum Therapeutics plc (NASDAQ:ITRM) does about 1.28M shares in volume on a normal day but saw 241457 shares change hands in Friday trading. The company now has a market cap of 22.36M USD and an enterprise value of about $-84.07%. Its current market price is $1.04, marking a decrease of -0.95% compared to the previous close of $1.05. The 52 week high reached by this stock is $7.65 whilst the lowest price level in 52 weeks is $0.92. The script in recent trading has seen the stock touch a high of $1.1086 and a low of $1.04.

Iterum Therapeutics plc (ITRM) has a 20-day trading average at $1.1198 and the current price is -86.41% off the 52-week high compared with 13.04% distance from its 52-week low. The 50-day simple moving average of the closing price is $1.6582 and its 200-day simple moving average is $2.6021. If we look at the stock’s price movements over the week, volatility stands at 5.16%, which increases to 6.70% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 37.30 to suggest the stock is neutral.

4 analysts observing the Iterum Therapeutics plc (ITRM) stock have set the 12-month price targets for the company’s shares at between $1.00 and $9.00. The median price target is 48.0% away from the current levels at $2.00.

FactSet Research has provided data showing that 4 brokerages have issued ratings for the stock. 1 analysts have rated it as a sell, while 0 advise that it is a overweight. 0 analysts have rated it as a buy and 3 have advised that investors hold their positions. The consensus recommendation rating is Underweight and Wall Street’s advice is for investors to Hold the stock.

The company shares received a number of brokerage firm price updates over the past month, with the latest being on June 02, 2020 when RBC Capital Mkts downgraded the stock to “Sector Perform” and issued a price target of between $7 and $2. Gabelli & Co also downgraded the stock to “Sell” from Buy on January 21, 2020 at a price target of . SVB Leerink downgraded its price target at .

The current price level is -7.74%, -39.39%, and -60.25% away from its SMA20, SMA50, and SMA200 respectively, with the ITRM price moving above the 50-day SMA on July 31. Iterum Therapeutics plc (ITRM) stock is down -7.96% over the week and -12.61% over the past month. Its price is -76.89% year-to-date and -84.22% over the past year.

The stock last released its quarterly earnings report for quarter ended 3/30/2020, with the company’s earnings per share (EPS) of -$1.08 above consensus estimates by $0.26. The company’s next earnings report is expected on 08/12/2020, with forecasts estimating quarterly EPS at -$0.81 and -$2.97 for whole year. ITRM’s earnings per share are forecast to grow by 58.20% this year and 24.20% over next year.

Its 12-month price target is $2.00. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $1.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $9.00.

Outstanding shares total 14.87M with insiders holding 3.58% of the shares and institutional holders owning 70.07% of the company’s common stock. The company has a return on equity of 848.60%.

According to a U.S. Securities and Exchange Commission filing, JNL Multi-Manager Small Cap Growt has added its position in Iterum Therapeutics plc (ITRM) to 158,500 shares, mirroring a recent increase by 6.52%. JNL Multi-Manager Small Cap Growt added 9700.0 shares of Iterum Therapeutics plc common stock bringing its total worth to about $0.19 million at the end of recent close, SEC documents show. JNL Multi-Manager Small Cap Growt isn’t the only investment manager who changed stakes and is followed by Abante Global Funds – Biotech Fun, which added 31351.0 shares to end up with 66,600 shares worth $79254.0. Destra Granahan Small Cap Advanta raise their holdings by 173.62% in the company over the course of the most recent quarter. It now holds a 0.00% position in Iterum Therapeutics plc thanks to 892.0 shares amounting to $1061.0.